Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass

[en] Background: Exposure of blood to polyanionic artificial surfaces, for example, during cardiopulmonary bypass (CPB), induces a highly procoagulant condition requiring strong anticoagulation. Unfractionated heparin (UFH) is currently used during CPB but can lead to serious bleeding complications or development of a hypercoagulable state culminating in life-threatening thrombosis, highlighting the need for safer antithrombotics. Ixodes ricinus contact phase inhibitor (Ir-CPI) is a protein expressed by I. ricinus ticks, which specifically inhibits both factors XIIa and XIa, 2 factors contributing to thrombotic disease while playing a limited role in hemostasis. Objectives: This study assessed the antithrombotic activity of Ir-CPI in animal contact phase-initiated thrombosis models, including CPB. The safety of Ir-CPI also was evaluated. Methods: The authors evaluated the antithrombotic activity of Ir-CPI by using in vitro catheter-induced clotting assays and rabbit experimental models of catheter occlusion and arteriovenous shunt. During CPB with cardiac surgery in sheep, the clinical applicability of Ir-CPI was investigated and its efficacy compared to that of UFH using an uncoated system suitable for adult therapy. Taking advantage of the similar hemostatic properties of pigs and humans, the authors performed pig liver bleeding assays to evaluate the safety of Ir-CPI. Results: Ir-CPI prevented clotting in catheter and arteriovenous shunt rabbit models. During CPB, Ir-CPI was as efficient as UFH in preventing clot formation within the extracorporeal circuit and maintained physiological parameters during and post-surgery. Unlike UFH, Ir-CPI did not promote bleeding. Conclusions: Preclinical animal models used in this study showed that Ir-CPI is an effective and safe antithrombotic agent that provides a clinically relevant approach to thrombosis prevention in bypass systems, including highly thrombogenic CPB. © 2019 The Authors

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Pireaux, V.; Bioxodes S.A., Marche-en-Famenne, Belgium

Tassignon, J.; Bioxodes S.A., Marche-en-Famenne, Belgium

Demoulin, S.; Bioxodes S.A., Marche-en-Famenne, Belgium

Derochette, S.; Bioxodes S.A., Marche-en-Famenne, Belgium

Borenstein, N.; IMM Recherche, Institut Mutualiste Montsouris, Paris, France

Ente, A.; IMM Recherche, Institut Mutualiste Montsouris, Paris, France

Fiette, L.; IMM Recherche, Institut Mutualiste Montsouris, Paris, France

Douxfils, J.; QUALIblood S.A., Namur, Belgium

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

Guyaux, M.; Bioxodes S.A., Marche-en-Famenne, Belgium

Godfroid, E.; Bioxodes S.A., Marche-en-Famenne, Belgium

Language :

English

Title :

Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass

Publication date :

2019

Journal title :

Journal of the American College of Cardiology

ISSN :

0735-1097

eISSN :

1558-3597

Publisher :

Elsevier USA

Volume :

Issue :

Pages :

2178-2189

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 June 2020

Statistics

Number of views

46 (1 by ULiège)

Number of downloads

235 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008;111:4871-4879.
Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:257S-298S.
Arepally GM. Heparin-induced thrombocytopenia. Blood 2017;129:2864-2872.
Bagheri K, Honarmand A, Safavi M, Kashefi P, Sayadi L, Mohammadinia L. The evaluations of frequency distribution heparin resistance during coronary artery bypass graft. Adv Biomed Res 2014;3:53.
Kawatsu S, Sasaki K, Sakatsume K, et al. Predictors of heparin resistance before cardiovascular operations in adults. Ann Thorac Surg 2018;105:1316-1321.
Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271-281.
Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006;203:513-518.
Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011;118:5302-5311.
Pauer HU, Renne T, Hemmerlein B, et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 2004;92:503-508.
Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014;6:222ra17.
van Montfoort ML, Knaup VL, Marquart JA, et al. Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model. Thromb Haemost 2013;110:1065-1073.
Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 2003;102:953-955.
Matafonov A, Leung PY, Gailani AE, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014;123:1739-1746.
Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol 2013;33:1670-.
Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696-701.
Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008;111:4113-4117.
Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 2011;105:269-273.
Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009;7 Suppl 1:84-87.
Gidley GN, Holle LA, Burthem J, Bolton-Maggs PHB, Lin FC, Wolberg AS. Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency. Blood Adv 2018;2:1076-1088.
Maritz-Olivier C, Stutzer C, Jongejan F, Neitz AW, Gaspar AR. Tick anti-hemostatics: targets for future vaccines and therapeutics. Trends Parasitol 2007;23:397-407.
Decrem Y, Rath G, Blasioli V, et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009;206:2381-2395.
Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 2011;118:6667-6674.
Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 2000;292:351-357.
Xu Y, Cai TQ, Castriota G, et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 2014;111:694-704.
Saeed D, Fukamachi K. In vivo preclinical anticoagulation regimens after implantation of ventricular assist devices. Artif Organs 2009;33:491-503.
Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 2014;123:2102-2107.
Landis RC, Brown JR, Fitzgerald D, et al. Attenuating the systemic inflammatory response to adult cardiopulmonary bypass: a critical review of the evidence base. J Extra Corpor Technol 2014;46:197-211.
Keularts IM, Zivelin A, Seligsohn U, Hemker HC, Beguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001;85:1060-1065.
Adams GL, Manson RJ, Hasselblad V, Shaw LK, Lawson JH. Acute in-vivo evaluation of bleeding with Gelfoam plus saline and Gelfoam plus human thrombin using a liver square lesion model in swine. J Thromb Thrombolysis 2009;28:1-5.
Leixnering M, Reichetseder J, Schultz A, et al. Gelatin thrombin granules for hemostasis in a severe traumatic liver and spleen rupture model in swine. J Trauma 2008;64:456-461.
Bilgili H, Kosar A, Kurt M, et al. Hemostatic efficacy of Ankaferd Blood Stopper in a swine bleeding model. Med Princ Pract 2009;18:165-169.
Bochicchio G, Kilbourne M, Kuehn R, Keledjian K, Hess J, Scalea T. Use of a modified chitosan dressing in a hypothermic coagulopathic grade V liver injury model. Am J Surg 2009;198:617-622.
Finley A, Greenberg C. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg 2013;116:1210-1222.
Bakchoul T, Zollner H, Amiral J, et al. Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood 2013;121:2821-2827.
Lee GM, Welsby IJ, Phillips-Bute B, Ortel TL, Arepally GM. High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood 2013;121:2828-2835.
Despotis GJ, Joist JH, Hogue CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54.
Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36-45.